Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Enrolls First Patient In Phase 2/3 Trial Of Bhv-3500, Third-generation Cgrp Receptor Antagonist, For The Acute Treatment Of Migraine
LPNEWS

Biohaven Enrolls First Patient In Phase 2/3 Trial Of Bhv-3500, Third-generation Cgrp Receptor Antagonist, For The Acute Treatment Of Migraine

by prnewswire.com posted 4months ago 159 views
NEW HAVEN, Conn., April 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced that it enrolled the first patient in a Phase 2/3,...

In this article